Zynerba Pharmaceuticals Reports First Quarter 2023 Financial

*Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024
*$44.4 million in cash and cash... | May 16, 2023

Related Keywords

Lincoln Park , Illinois , United States , Chicago , Armando Anido , Jim Fickenscher , Peter Vozzo , Canaccord Genuity , Mackenzie Partners Inc , Ladenburg Thalmann Co , Exchange Commission , Zynerba Pharmaceuticals Inc , Vp Corporate Development , Cantor Fitzgerald Co , Company Proxy Statement For The Annual Meeting , European Medicines Agency , Company Board , Drug Administration , Lincoln Park Capital Fund , Hc Wainwright Co , Nasdaq , European Commission , Zynerba Pharmaceuticals , Nasdaq Capital , Chief Executive Officer , Fragilex Syndrome , New Drug Application , Marketing Authorization Application , Social Avoidance , Press Release , Pediatric Anxiety Rating Scale , Mood Scale , Aberrant Behavior Checklist , Annual Meeting , Proxy Statement , Nasdaq Capital Market , Kenzie Partners , Controlled Equity , Purchase Agreement , Park Capital Fund , Fast Track , Private Securities Litigation Reform Act , Medicines Agency , Stockholder Equity Current , Nc Stock Exchange , News , Information , Ontinues , N , Confirmatory , Pivotal , Hase , , Trial , F , Ygel , Patients , Ith , Fragile , Topline , Results , Xpected , Billion , Cash , Nd Zyne Us98986x1090 ,